Scientists test Triple-Threat attack on Tough-to-Treat blood cancer
Disease control
Recruiting now
This study is testing a new combination treatment for aggressive non-Hodgkin lymphoma that has returned or not responded to standard therapies. It will give 22 patients a three-part regimen: first a personalized cell therapy (CAR-T), followed by two other drugs. The main goal is …
Phase: PHASE2 • Sponsor: Lazaros Lekakis • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC